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Background. Dual therapy (DT) with boosted protease inhibitors (bPIs) plus lamivudine has been shown to be superior to bPI 
monotherapy in virologically suppressed patients despite previous selection of the lamivudine resistance M184V mutation. We com-
pared the virological efficacy of lamivudine-based DT in patients with and without a history of M184V detection.
Methods. We retrospectively analyzed patients with HIV-RNA ≤50 copies/mL switching to DT with at least 1 previous resist-
ance genotype in the ARCA database. Time to virological failure (VF; HIV-RNA ≥200 copies/mL or 2 consecutive HIV-RNA >50 
copies/mL) and to treatment discontinuation (TD) was analyzed by survival analysis.
Results. Four hundred thirty-six patients switching to lamivudine plus bPIs (70%) or integrase inhibitors (30%) were included. 
Patients with M184V (n = 87) were older, had lower nadir CD4+ cell count, longer duration of antiretroviral therapy and of virologic 
suppression, and higher rate of hepatitis C virus infection compared with patients without M184V. The 3-year probability of remain-
ing free from VF was 91.9% (95% confidence interval [CI], 86.6–97.2) without M184V and 87.8% (95% CI, 78.4–97.2) with M184V 
(P = .323). The time to TD did not differ between groups. Multivariate analysis adjusting for baseline variables differing between 
groups also did not detect M184V as being associated with VF or TD; however, the 3-year probability of remaining free of viral blips 
(isolated HIV-RNA 51–199 copies/mL) was 79.8% (95% CI, 67.8%–91.8%) with M184V vs 90.1% (95% CI, 84.0%–96.2%) without 
M184V (P = .016).
Conclusions. Previous selection of M184V did not increase the risk of VF or TD with lamivudine-based DT but was associated 
with a higher probability of viral blips.
Keywords. dual therapy; integrase inhibitors; lamivudine; M184V; NRTI mutations.
 
Combination antiretroviral therapy (ART) has radically 
changed the clinical course of HIV disease, reducing AIDS-
related morbidity and mortality [1]. The disease has become 
chronic and requires life-long treatment, raising issues of treat-
ment tolerability, toxicity, and adherence. Thus, several strate-
gies of ART regimen simplification have been considered. Dual 
therapies (DTs) have been explored in a significant number of 
randomized clinical trials and are increasingly being used as 
maintenance therapy, particularly in some European countries. 
Lamivudine is the companion drug for many of the dual regi-
mens investigated so far [2–7]. A meta-analysis of randomized 
trials showed a noninferior risk of virological failure with lam-
ivudine plus boosted protease inhibitor (bPI) as compared 
with continuation of the 3-drug regimen [8]. Interestingly, the 
ANRS12286/MOBIDIP trial showed the superiority of DT with 
lamivudine plus bPI as compared with bPI monotherapy in a 
population of patients virologically suppressed on a second-line 
regimen of 2NRTI plus bPI, carrying the M184V mutation in 
many cases [9].
The M184V mutation is associated with high-level in vitro resist-
ance to lamivudine but also with reduced viral replication capacity 
[10]. Previous selection of M184V may impact clinical decisions 
to implement lamivudine-containing DT, yet a direct compari-
son of efficacy in patients harboring or not harboring the M184V 
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mutation has not been performed. This study aimed at compar-
ing the virological efficacy of lamivudine-based maintenance 
DT in clinical practice patients with suppressed viral load, with 
(M184V+) or without (M184V-) a history of M184V detection.
METHODS
Patients Selection Criteria and Virological Characteristics
This is a retrospective observational study performed using the 
Antiviral Response Cohort Analysis (ARCA) database, which 
contains data on HIV resistance and antiretroviral therapy 
from >40 000 patients in Italy [11]. The study was performed in 
accordance with the ethical standards of the 1964 Declaration of 
Helsinki and later amendments. All patients signed an informed 
consent for use of their clinical and laboratory data in aggregated 
and anonymous form. Access to the database and data analyses 
were regulated by local institutional ethics committees and by 
Italian and European privacy legislation. The ARCA database 
was queried to retrieve the data of HIV-1-infected patients with 
(i) age ≥18 years, (ii) HIV-RNA ≤50 copies/mL on any ART reg-
imen, (iii) subsequently switching to DT (lamivudine plus bPI 
or plus integrase inhibitor [INI]) for any reason, (iv) with at least 
1 previous genotype, (v) with at least 1 virological and clinical 
follow-up after switching to DT. The occurrence of M184V was 
assessed using historical genotypic resistance tests (hGRTs); that 
is, any detection of this mutation in any previous resistance test 
was scored as positive. In a sensitivity analysis, only the most 
recent resistance genotype before baseline was considered. 
Patients treated with bPI monotherapy were selected with the 
same inclusion criteria (i–ii and iv–v) and were used as an add-
itional control group.
A genotypic sensitivity score (GSS) was derived for each drug 
accompanying lamivudine (for the DT group) or for each mon-
otherapy, based on the hGRT according to the AntiRetroScan 
2.0 genotypic interpretation system, as detailed elsewhere [12]. 
Briefly, a GSS of 0 was assigned if the system interpreted “no 
activity,” 0.25 if “minimal activity,” 0.50 if “partial activity,” 0.75 if 
“good activity,” and 1 if “complete activity” [11]. For INI therapies 
without INI sequences available before BL, GSS was assigned as 1.
End Points and Statistical Analysis
The primary objective of the study was to compare time to viro-
logical failure and time to treatment discontinuation between 
the M184V- and M184V+ groups. Secondary objectives were to 
compare time to virological blips between the 2 groups and time 
to virological failure between the DT group (overall and with 
M184V+) and the bPI monotherapy group. Virological fail-
ure was defined as HIV-RNA >50 copies/mL in 2 consecutive 
determinations or ≥200 copies/mL in a single determination. 
Treatment discontinuation was defined as discontinuation of 
current DT for any reason or loss to follow-up. Viral blips were 
defined as a single HIV-RNA between 51 and 199 copies/mL 
preceded and followed by ≤50 copies/mL measurements.
Differences between groups were investigated by the Student 
t test and chi-square analysis. Standard survival analyses with 
Kaplan-Meier curves were used to analyze time to virological 
failure, time to treatment discontinuation, and time to viral 
blip. Patients were followed from baseline (ie, start of DT) to the 
study outcomes, last available follow-up, or February 28, 2017, 
whichever occurred first. For the time to viral blip analysis, 
patients with virological failure were excluded. Predictors were 
investigated by univariate Cox regression; variables showing a 
significant association at univariate analysis and those variables 
for which the 2 groups differed at baseline were evaluated in 
multivariable models. P values of less than .05 were considered 
significant.
We performed sensitivity analyses considering M184V 
only in the last available genotypic resistance tests and a dif-
ferent definition of virological failure (HIV-RNA >50 copies/
mL in 2 consecutive determinations or a single determination 
≥1000 copies/mL) and of virological blips (single HIV-RNA 
between 51 and 999 copies/mL not confirmed at the subsequent 
determination).
All analyses were executed using the SPSS v.22.0 software 
package.
RESULTS
Patients
A total of 436 patients starting lamivudine-based DT were 
selected, of which 349 (80%) did not have the M184V mutation 
and 87 (20%) did have the M184V mutation, according to the 
hGRT (patients’ baseline characteristics in Table 1). DTs started 
at baseline were lamivudine plus bPI (70%; lopinavir/r [10%], 
atazanavir/r [24%], darunavir/r [36%]) and lamivudine plus 
INI (30%; dolutegravir [29%], raltegravir [1%]).
Virological Failure and its Predictors
Main Results
In the DT group, during 693 person-years of follow-up (PYFU; 
median follow-up, 1.3 years; interquartile range [IQR], 0.7–2.5), 
24 virological failures were detected: 7 during 139 PYFU in 
M184V+ patients (incidence, 5.1; 95% confidence interval [CI], 
2.2%–9.9% per 100 PYFU) and 17 during 554 PYFU in M184V- 
patients (incidence, 3.1; 95% CI, 1.8%–4.8% per 100 PYFU). 
Virological failures were 4 on lamivudine plus atazanavir/r 
and 3 on lamivudine plus darunavir/r in the M184V+ group, 7 
on lamivudine plus atazanavir/r, 5 on lamivudine plus darun-
avir/r, 3 on lamivudine plus lopinavir/r, and 2 on lamivudine 
plus dolutegravir in the M184V- group. GRT after virological 
failure was available only for 8 patients, all in lamivudine +bPI 
(Supplementary Table 1).
The estimated probability of remaining free from virological 
failure was comparable in the 2 groups: at 1 year 95.1% (95% 
CI, 89.6–100.6) in M184V+ and 96.2% (95% CI, 93.9–98.6) 
in M184V- patients; at 3  years 87.8% (95% CI, 78.4–97.2) in 
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M184V+ and 91.9% (95% CI, 86.6–97.2) in M184V- patients 
(P = .323) (Figure 1A).
Subanalyses
In a sensitivity analysis, where only a subset of 85 patients were 
classified in the M184V+ group based on the last available 
genotypic resistance test, almost identical virological outcomes 
were observed (Supplementary Figure 1A).
At a further sensitivity analysis using the more stringent def-
inition of virological failure, as defined in the “Methods” and 
according to the hGRT, the probabilities of remaining free 
from virological failure in M184V+ and M184V- were similar 
(Supplementary Figure 1B).
To minimize the difference in duration of viral suppression 
before baseline between the groups, an analysis selecting patients 
with viral suppression of equal to or less than 6.6 years (the me-
dian duration of viral suppression in the M184V+ group) was 
performed (n = 308: 265 in the M184V- group and 43 in the 
M184V+ group). In this subset, the 1- and 3-year probabilities 
of remaining free from virological failure were, respectively, 
94.4% (95% CI, 87.0–101.8) and 82.9% (95% CI, 67.2–98.6) in 
the M184V+ group and 97.3% (95% CI, 95.1–99.5) and 92.5% 
(95% CI, 86.8–98.2) in the M184V- group (P  =  .080). In an 
additional analysis selecting patients with equal to or less than 
3 years of viral suppression, the respective 1- and 3-year prob-
abilities of remaining free from virological failure were 100.0% 
Table  1. Baseline Characteristics of Patients Starting Lamivudine-Based Dual Therapies According to M184V Detection in the 
Historical Genotypic Resistance Test
M184V- (n = 349) M184V+ (n = 87) P
Age, ya 46 (39–53) 52 (48–57) <.001
Male sex 257 (72) 53 (61) .019
Caucasians 308 (88) 84 (97) .077
Risk factor
 Sexual 225 (64) 56 (64) .001
 IDU 40 (11) 21 (24)
 Other/unknown 84 (24) 10 (11)
HCV infection 62 (18) 24 (28) <.001
HBsAg+ 12 (3) 2 (2) .001
Previous AIDS events 40 (12) 16 (18) .084
HIV-RNA at zenith, cp/mLa 104 750 (35 807–329 250) 107 910 (27 000–252 900) .416
Years from HIV diagnosisa 7.8 (3.8–13.7) 19.2 (16.1–23.0) <.001
Years from first ART initiationa 5.6 (2.8–10.0) 16.6 (12.8–18.9) <.001
Duration of viral suppression, ya 3.8 (2.2–6.4) 6.6 (3.7–8.9) <.001
Lines of ARTa 4 (3–6) 8 (7–13) <.001
Nadir CD4+, cells/µLa 224 (81–313) 147 (57–199) <.001
Current CD4+, cells/µLa 620 (453–780) 632 (409–922) .131
Type of DT
 Lamivudine + bPI 242 (69) 64 (74) .441
 Lamivudine + bDRV 122 (35) 33 (38)
 Lamivudine + bLPV 34 (10) 11 (13)
 Lamivudine + bATV 86 (24) 20 (23)
 Lamivudine + INI 107 (31) 23 (26)
 Lamivudine + DTG 105 (30) 21 (24)
 Lamivudine + RAL 2 (1) 2 (2)
Pre-BL ART
 2NRTI + PI 176 (50) 44 (51) .081
 2NRTI + INI 26 (7) 7 (8)
 2NRTI + NNRTI 45 (13) 3 (3)
 DT 79 (23) 23 (26)
 Other 23 (7) 10 (12)
Calendar yeara 2014 (2013–2015) 2014 (2012–2015) .121
GSS of the 2nd drugb 0.99 (0.07) 0.91 (0.20) <.001
Major PI resistance mutationsc 13 (4) 30 (34) <.001
Abbreviation: ART, antiretroviral therapy; ATV, atazanavir; BL, baseline; bPI, boosted protease inhibitors; DRV, darunavir; DT, dual therapy; lamivudine, lamivudine; DTG, dolutegravir; GSS, 
genotypic sensitivity score; IDU, injective drug users; INI, integrase inhibitor; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; LPV, lopinavir; NNRTI, non-nucleoside reverse-tran-
scriptase inhibitors; NRTI, nucleoside reverse-transcriptase inhibitors; RAL, raltegravir.
Values are expressed as n (%) except for amedian (IQR) and bmean (SD). Significant P values (<.05) are in bold.
cAt least 1 major PI resistance mutation at the hystorical genotype according to Stanford hivdb [22].
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and 67.7% in the M184V+ group and 97.3% an 96.2% in the 
M184V- group (P  =  .002) (Figure  1B). A  sensitivity analysis 
considering only patients with more than 1 year of viral sup-
pression showed similar results. No differences in virological 
failure were detected when DT with lamivudine + bPI was com-
pared with lamivudine + INI (Supplementary Figure 1C).
When compared with the bPI monotherapy group (patients’ 
baseline characteristics are in Supplementary Table 2), DT per-
formed better; the 3-year estimated probabilities of remaining 
free from virological failure were 74.7% (95% CI, 65.9–92.3) 
with monotherapy and 91.1 % (95% CI, 86.4–95.8) with DT 
(P  <  .001). Even DT with previous detection of M184V per-
formed better than bPI monotherapy: 87.8% (95% CI, 78.4–97.2) 
vs 74.7% (95% CI, 65.9–92.3), but without a statistically signifi-
cant difference (P = .099). At Cox regression analysis, adjusting 
for hepatitis C virus (HCV) serostatus, duration of viral sup-
pression, M184V status, and GSS of the regimen, being on a DT 
regimen (adjusted hazard ratio [aHR], 0.33; 95% CI, 0.14–0.81; 
P = .015) was independently associated with a lower risk of viro-
logical failure, whereas HBsAg positivity predicted a higher risk 
of virological failure (aHR, 2.96; 96% CI, 1.17–7.45; P = .022).
In the DT group, at univariate analysis, being HBsAg-positive, 
a longer history of ART, a higher HIV-RNA at zenith, and a 
lower GSS of the accompanying drug (bPI or INI) resulted in an 
association with greater risk of virological failure (Table 2). In 
a multivariate model adjusting for virological factors (duration 
of viral suppression, HIV-RNA at zenith, M184V, GSS of the 
accompanying drug), only higher HIV-RNA at zenith and lower 
GSS of the accompanying drug, but not M184V, were inde-
pendently associated with virological failure, whereas another 
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Figure 1. a: Estimated probability of being free from virological failure (VF) with dual therapy (M184V groups based on the hGRT). b: Estimated probability of being free 
from virological failure (VF) in the overall population of dual therapy and in patients with shorter time of viral suppression (M184V groups based on the hGRT). c: Estimated 
probability of being free from treatment discontinuation (TD) with dual therapy (M184V groups based on the hGRT). d: Estimated probability of being free from virological 
blips (VB) with dual therapy (M184V groups based on the hGRT).
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model including HBsAg status, time of viral suppression, age, 
sex, HIV-RNA at zenith, M184V, and GSS of the accompany-
ing drug showed an independent association between HBsAg 
positivity and virological failure and confirmed that lower GSS 
is probably linked to virological failure (Table 2). A sensitivity 
analysis excluding patients previously exposed to INI without 
INI sequences available before baseline (n = 398) showed simi-
lar results (not shown).
Treatment Discontinuation and its Predictors
During an overall 724 PYFU, 36 treatment discontinuations 
occurred in the M184V+ group during 153 PYFU, and 131 in 
the M184V- group during 571 PYFU (incidence, 23.5 and 22.9 
per 100 PYFU, respectively; P =  .332). Causes of treatment dis-
continuation were toxicity (55 in the M184V- group and 10 in 
the M184V+ group), virological failure (5 and 3, respectively), 
further simplification (23 and 6), and other (48 and 17). The 
estimated probabilities of remaining free from treatment discon-
tinuation were also similar in the 2 groups: at 1 year 84.9% (95% 
CI, 80.8–89.0) in the M184V- and 83.3% (95% CI, 74.4–91.7) in 
the M814V+ group; at 3 years 44.6% (95% CI, 37.2–53.0) in the 
M184V- group and 48.8% (95% CI, 32.9–64.7) in the M184V+ 
group (P =  .847) (Figure 1C). At a sensitivity analysis consider-
ing the last available genotypic resistance test, similar results 
were obtained (not shown). The only predictor of treatment 
discontinuation at univariate analysis was HBsAg positivity (HR, 
2.42; 95% CI, 1.06–5.54; P = .037), which was confirmed in a mul-
tivariate model (aHR, 2.28; 95% CI, 0.99–5.27; P = .053) adjusting 
for duration of viral suppression, age, sex, and M184V status.
Viral Blips and Their Predictors
Main Analysis
Viral blips occurred in 10 of 80 (13%) M184V+ patients dur-
ing 112 PYFU and 18 of 332 (5%) M184V- patients during 502 
PYFU. The estimated probabilities of remaining free of viral 
blips were lower in patients with previous detection of M184V: 
at 1 year 85.9% (95% CI, 76.7–95.1) vs 96.4% (95% CI, 94.2–
98.6) and at 3 years 79.8% (95% CI, 67.8–91.8) vs 90.1% (95% 
CI, 84.0–96.2) in the M184V- group (P = .016) (Figure 1D).
Subanalyses
At the sensitivity analysis considering the last available geno-
typic resistance test for M184V status classification, similar 
results were obtained (Supplementary Figure 1D).
In the subset of patients with viral suppression of ≤6.6 years, 
the difference in the 3-year probability of remaining free of blips 
was even larger (M184V+ group: 69.4%; 95% CI, 50.6–88.2; 
M184V- group: 91.1%; 95% CI, 84.8–97.4; P < .001).
At a further sensitivity analysis using a broader definition of 
viral blip (51–999 cp/mL; see the “Methods”), these occurred in 
Table 2. Predictors of Virological Failure With Lamivudine-Based Dual Therapies
Univariate Analysis Multivariable Analysis 1 Multivariable Analysis 2
Variables HR (95% CI) P Value aHR (95% CI) P Value aHR (95% CI) P Value
M184V in hGRT 1.56 (0.64–3.76) .327 1.23 (0.46–3.31) .684 1.11 (0.38–3.23) .847
Type of DT (PI vs INI) 0.42 (0.10–1.85) .251
Age (+10 y) 1.17 (0.83–1.65) .381 1.11 (0.73–1.69) .625
Gender (male vs female) 0.66 (0.29–1.50) .320 0.61 (0.25–1.51) .284
Ethnicity (Caucasian vs other) 0.60 (0.14–2.54) .483
Risk factor (ref. sexual)
 IDU 2.40 (0.85–6.75) .098
 Other/unknown 1.51 (0.57–4.02) .411
HCV infection (ref. absent)
 Present 1.85 (0.78–4.37) .163
 Unknown 0.16 (0.02–1.19) .073
HBsAg (ref. negative)
 Positive 8.85 (2.25–31.5) .001 12.53 (2.15–72.96) .005
 Unknown 0.50 (0.15–1.71) .269 1.67 (0.46–5.96) .437
Previous AIDS-defining events 1.34 (0.46–3.93) .594
Time from first ART initiation (+1 y) 1.07 (1.01–1.13) .032
Duration of virological suppression before 
baseline (+1 y)
0.97 (0.86–1.16) .965 0.95 (0.81–1.1) .949 0.92 (0.79–1.08) .306
Baseline CD4+ counts (+100 cells/µL) 0.99 (0.86–1.14) .922
Nadir CD4+ counts (+100 cells/µL) 0.86 (0.64–1.16) .319
Zenith HIV-RNA (+1 log10 copies/mL) 1.91 (1.06–3.42) .030 1.91 (1.05–3.49) .035 1.61 (0.89–2.91) .116
GSS of the 2nd drug (+0.5) 0.36 (0.16–0.84) .018 0.41 (0.16–1.03) .058 0.41 (0.15–1.19) .082
Abbreviations: aHR, adjusted hazard ratio; ART, combined antiretroviral therapy; DT, dual therapy; GSS, genotypic sensitivity score; HBsAg, hepatitis B surface antigen; HCV, hepatitis C 
virus; hGRT, historical genotype resistance test; HR, hazard ratio; IDU, injective drug users; INI, integrase inhibitor, PI, protease inhibitors. Significant P values (<.05) are in bold.
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20 of 335 (6%) M184V- and 13 of 83 (16%) M184V+ patients 
(based on the hGRT classification). The 3-year estimated prob-
abilities of remaining free from viral blips were similar to the 
ones in the main analysis (Supplementary Figure 1E).
At multivariable Cox regression analysis, HCV infection and 
presence of M184V at hGRT were independently associated 
with a higher risk of viral blips (Table 3). In a different model 
also adjusting for baseline variables that were different between 
the 2 M184V groups (age, duration of viral suppression, CD4 at 
nadir, GSS of the accompanying drug), HCV infection (aHR, 
2.96; 95% CI, 1.21–7.24; P = .017) and M184V at hGRT (aHR, 
2.55; 95% CI, 0.98–6.62; P = .052) were confirmed as independ-
ently associated with viral blips.
DISCUSSION
Several randomized studies have shown noninferiority of lam-
ivudine with bPI in virologically suppressed individuals, with 
respect to triple therapy [2–5]. DT with lamivudine and dolute-
gravir was also effective in a single-arm prospective study [6]. 
However, these studies excluded patients with previous resistance 
to the study drugs. Here we show that a previous selection of the 
M184V mutation has no major impact on the virological efficacy 
of lamivudine-based DT as a maintenance regimen. This finding 
was consistent throughout several sensitivity analyses using dif-
ferent classifications of M184V detection and virological failure. 
Multivariable analysis adjusting for factors differing between the 
M184V-positive and -negative groups at DT initiation confirmed 
the lack of association of this substitution with virological failure. 
DTs were also more effective than bPI monotherapies, independ-
ently from M184V. Moreover, we found no impact of previous 
M184V detection of the durability of lamivudine-based DT.
This is the first study directly comparing the efficacy of lam-
ivudine-based DT in patients with or without previous detec-
tion of the M184V substitution. The ANRS12286/Mobidip trial 
demonstrated superior virological efficacy of lamivudine plus 
bPI over bPI monotherapy in patients on an undetectable viral 
load on bPI-based second-line therapy. In that study, all patients 
had a previous virological failure on a NNRTI-based firstline 
therapy, and their viruses harbored multiple mutations (97% 
had M184V, 59% at least 1 and 27% at least 3 thymidine ana-
logue mutations) [9]. Our study confirms the efficacy of lam-
ivudine-based DT in patients previously selecting the M184V 
mutation, despite relevant differences between the 2 studies in 
term of design, resource setting, population characteristics, and 
virological failure definition. In line with Mobidip, we also show 
lower rates of virologic failure with DT than with bPI mono-
therapy, even in patients harboring M184V, even though only 
the comparison between DT overall vs monotherapy reached 
statistical significance, not the one between DT with previous 
selection of the M184V vs monotherapy, probably due to the 
limited sample size. It has to be highlighted that the chosen 
comparator was PI monotherapy, not triple therapy, to test 
whether the lamivudine-based DT in patients carrying M184V 
could be considered “functional” monotherapy.
Table 3. Predictors of Viral Blips With Lamivudine-Based Dual Therapies
Univariate Analysis Multivariable Analysis
Variables HR (95% CI) P Value aHR (95% CI) P Value
M184V in hGRT 2.51 (1.15–5.44) .020 2.45 (1.09–5.53) .030
Type of DT (PI vs INI) 0.56 (0.19–1.63) .284
Age (+10 y)
Gender (male vs female) 1.79 (0.68–4.70) .241
Ethnicity (Caucasian vs other) 1.38 (0.18–10.20) .751
Risk factor (ref. sexual)
 IDU 1.57 (0.53–4.68) .420
 Other/unknown 1.20 (0.54–3.14) .558
HCV infection (ref. absent)
 Present 2.89 (1.21–6.87) .017 2.71 (1.14–6.48) .025
 Unknown 1.28 (0.50–3.25) .607 1.57 (0.60–4.09) .361
HBsAg (ref. negative)
 Positive 0.00 (0.00–0.01) .975
 Unknown 1.17 (0.50–2.75) .725
Previous AIDS-defining events 1.08 (0.38–3.13) .883
Time from first ART initiation (+1 y) 1.04 (0.98–1.10) .188
Time of virological suppression (+1 y) 1.02 (0.90–1.16) .753
Baseline CD4+ (+100 cells/µL) 1.07 (0.95–1.21) .233
Nadir CD4+ (+100 cells/µL) 0.95 (0.73–1.22) .671
Log zenith HIV-RNA 1.10 (0.66–1.82) .721
GSS of the 2nd drug (+0.5) 0.29 (0.08–1.56) .113
Abbreviations: aHR, adjusted hazard ratio; ART, combined antiretroviral therapy; DT, dual therapy; GSS, genotypic sensitivity score; HBsAg, hepatitis B surface antigen; HCV, hepatitis C 
virus; hGRT, historical genotype resistance test; HR, hazard ratio; IDU, injective drug users; INI, integrase inhibitor, PI, protease inhibitors. Significant P values (<.05) are in bold.
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Observational studies with small sample size and short 
follow-up also support the view that past M184V has no impact 
on the efficacy of lamivudine plus dolutegravir. In a prospective 
study of 27 patients, 8 carried the M184V mutation in their 
hGRT, and none of them experienced virological failure in the 
first year of DT [7], whereas in a cohort of 36 patients switching 
to this dual regimen, 3 had a prior detection of M184V, and 
none of these experienced virological failure [13].
One possible explanation for the absence of a major negative 
impact of the prior M184V mutation on the efficacy of lami-
vudine-based DT could be its association with decreased viral 
fitness and with lower replication capacity, lowering the prob-
ability of virus rebound [10, 14, 15]. Moreover, recent in vitro 
studies indicated a protective role of M184V against the selec-
tion of dolutegravir resistance mutations, further explaining the 
lack of impact of this mutation on the efficacy of lamivudine 
plus dolutegravir [16]. Interestingly, in our cohort, 21 patients 
on lamivudine plus dolutegravir carried M184V, and none 
failed after a median follow-up of 10 months, whereas dolute-
gravir maintenance monotherapy studies have shown measur-
able failure rates during follow-up of similar duration [17, 18].
Although the main results did not show a significant role 
for M184V, some sensitivity analyses suggested an effect on 
treatment efficacy. In particular, in patients with a shorter dur-
ation of viral suppression before simplification to DT, the group 
with previous detection of M184V showed higher hazards of 
virological failure, and the gap of efficacy between the groups 
increased when reducing the duration of suppression, particu-
larly below 3 years. This trend is compatible with a progressive 
decline of the impact of M184V with increasing time since the 
mutation was last detected. Although the concept of a time-de-
pendent effect likely applies to any resistance mutation (ie, the 
longer the time the mutation has been not detected, the lower 
its impact on virological outcome), the declining effect could 
be faster for those variants with impaired replication, such as 
M184V. The size of the viral reservoir progressively decreases 
during the initial 3–4  years of suppressive ART and tends to 
plateau thereafter [19]. Longer duration of viral suppression 
could disproportionally reduce the size of the reservoir of rep-
lication-impaired viruses because of reduced probability to re-
seed the reservoir in the context of residual replication under 
suppressive therapy [20, 21]. Measuring the dynamics of M184V 
HIV-DNA relative to total HIV-DNA levels over time under 
suppressive therapy would be required to test this hypothesis. 
Although the mechanism underlying the time-dependent effect 
of M184V remains to be clarified, simplification to lamivu-
dine-based DT appears safer in patients carrying M184V who 
have been fully virologically suppressed for a longer period.
The higher rate of viral blips in patients with past M184V 
confirms that previous selection of M184V has some negative 
effect on maintaining complete viral suppression. However, 
this negative effect was probably mitigated by the activity of 
the drug accompanying lamivudine. In line with this hypoth-
esis, the GSS of the accompanying drug played a key role in pre-
dicting virological failure, together with the higher HIV-RNA 
zenith. These findings suggest that maintenance DT should be 
carefully selected based on prior virological history.
Finally, we found an expected negative impact of hepatitis B 
virus (HBV) co-infection on virological efficacy and durability, 
as HBsAg is a relative contraindication to lamivudine-contain-
ing DT, given lamivudine-limited anti-HBV activity and low 
genetic barrier to HBV resistance. Even if switching HBsAg+ 
patients to a regimen without tenofovir is not recommended, 
it could be partially explained by clinical practice mistakes or 
by the use of other HBV-active medications (eg, entecavir in 
patients with contraindications to tenofovir), but these data un-
fortunately were not available in the database.
This study presents some limitations. Due to its retrospective 
nature, significant confounders may have gone undetected. The 
achieved statistical power to detect differences between M184V 
groups for the main virological failure end point was low. Data 
about adherence were lacking, measures of medication adher-
ence and exposure were not available, and several baseline char-
acteristics differed between groups.
Nonetheless, when we adjusted the analyses for these char-
acteristics in several multivariable models, still no impact of 
M184V on virological failure was found.
In conclusion, DT with lamivudine plus bPI or dolutegravir 
could represent a safe and cheap strategy of ART simplification, 
both in resource-limited and high-income countries. Even in 
consideration of the efforts to reach universal access to ART, the 
possibility to prescribe maintenance regimens with lower tox-
icity and decreased cost could represent a significant advantage. 
Based on our findings, a previous selection of M184V should 
not represent a major obstacle to the efficacy of these regimens, 
provided that viral suppression has been consolidated and the 
activity of the drug accompanying lamivudine is fully preserved.
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